In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organon Reboots with Biotech

Executive Summary

Organon's biologics R&D push relects similar moves by other mid-sized firms, and could help the company recover after a series of setbacks. But building biotech from discovery upwards will take time.
Advertisement

Related Content

Private Equity Comes to Discovery
Schering-Plough Adds to Pipeline with Organon Acquisition
European Consolidation: Serious Competition for Big Pharma?
Solvay Pharma: Dealing Its Way Into the Limelight
Europe's Flavors of Sustainable BioPharma
Big Pharma's Large Molecule Challenge
Big Pharma's Large Molecule Challenge
Europe's Flavors of Sustainable BioPharma
Bioteching UCB-and Maybe Mid-Sized Pharma, Too
Bioteching UCB-and Maybe Mid-Sized Pharma, Too

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel